RxDoctor Payments Data

Kendall Clark

Family · Sylvania, GANPI 1821489337

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Lilly USA, LLC at 24.2% of the total. 2025 is the largest year on record at $89, 5.1 times the $18 reported in 2022. That places this record below the midpoint for family clinicians in GA, where the typical reported total is $363.

$249in general payments, 2019–2025

Across 14 payments — averaging $17.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$60
  • AbbVie$36
  • Amgen$32
  • AstraZeneca$29
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$25
  • Corcept Therapeutics$19
  • plus $49 from 3 others

What the payments were for

  • Food & beverage$249100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$249 in reported general payments places this provider in the 40th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia →

Medicare billing

Part B allowed, 2024
$33,113
Medicare patients
113
Services billed
813

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide78$96,321
Enbrel SureclickEtanercept12$90,139
OtezlaApremilast16$86,803
JanuviaSitagliptin Phosphate39$38,288
LinzessLinaclotide33$37,696
EliquisApixaban26$35,413
RybelsusSemaglutide21$32,031
JardianceEmpagliflozin18$30,575
TrulicityDulaglutide31$26,368
RexultiBrexpiprazole13$21,644
XareltoRivaroxaban12$12,434
Nurtec OdtRimegepant Sulfate11$11,052
Dexlansoprazole DrDexlansoprazole15$6,370
Levothyroxine Sodium156$2,204
Gabapentin107$1,711

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$60$122,689109 claims
AmgenOtezla$32$86,80316 claims
PfizerEliquis, Nurtec Odt$16$46,46537 claims
AbbVieLinzess$36$37,69633 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 6,258 family providers in Georgia.

Other family in Sylvania

See the full list for Georgia →

Where these figures come from

Is this you, or does something look wrong? →